Timely use of Novartis’ Entresto could save thousands of lives
Timely and broad adoption of Novartis’ Entresto by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the US alone, finds a new analysis published in JAMA Cardiology.
Read More
